Press releases

Press

Press releases

BEUC welcomes Commission fines on Teva and Cephalon for agreement to delay marketing of generic sleep drug
- PDF Document - 96.15 KB

Available in English
The European Consumer Organisation (BEUC) welcomes the European Commission’s decision today to fine Teva and Cephalon 30 and 30.5 million euros respectively for agreeing not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, in Europe for six years. The “pay for delay” agreement, which the Commission has found to violate EU antitrust rules, allowed Cephalon to charge European patients and healthcare systems higher prices for the drug in the six year period before Teva finally marketed its generic alternative.
Contact Card
Pauline Constant, BEUC
Pauline Constant
Director, Communications
Andrew Canning
Senior Communications Officer
Oriana Henry
Communications Officer
Sandrine Carpentier
Communications Officer